A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy

Figures & data

Table 1 A List of Common Cell-Surface and Intracellular Markers Pertaining to CSCs

Marker	Cancers (Found in)	Location
CD44	Melanoma,^Citation26 Oral Squamous Cell Carcinoma,^Citation27 Primary Pancreatic Cancer^Citation27	Cell Surface^Citation26
CD133	Colorectal Cancer,^Citation29 Breast Cancer^Citation30	Cell Surface^Citation29
ALDH1	Invasive Ductal Carcinoma (Breast Cancer),^Citation35 Ovary Adenocarcinoma,^Citation36 Liver Hepatocellular Carcinoma^Citation36	Intracellular^Citation36
TGF-β	Glioblastoma,^Citation1 Breast Cancer^Citation33	Cell Surface^Citation33

Figure 1 Therapeutic carrier models for cancer treatment. (Left) Cancer stem cells (CSCs) loaded with therapeutic cargo can be transplanted or delivered to site of tumor formation (tumor bed). (Right) Nanoparticles (NPs) targeting the CSCs can deliver chemotherapeutic payload and induce hyperthermia with an external applied magnetic field (AMF).

Dietrich A, Tanczos E, Vanscheidt W, Schopf E, Simon JC. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer. 1997;33(6):926–930. doi:10.1016/S0959-8049(96)00512-6

 PubMed Web of Science ®Google Scholar

Thapa R, Wilson GD. The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int. 2016;2016:2087204. doi:10.1155/2016/2087204

 PubMed Web of Science ®Google Scholar

Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111–2120. doi:10.1172/JCI34401

 PubMed Web of Science ®Google Scholar

Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V. CD133 in breast cancer cells: more than a stem cell marker. J Oncol. 2019;2019:7512632. doi:10.1155/2019/7512632

 PubMed Web of Science ®Google Scholar

Rabinovich I, Sebastiao APM, Lima RS, et al. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. Eur J Histochem. 2018;62(3). doi:10.4081/ejh.2018.2943.

 PubMed Web of Science ®Google Scholar

Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7(10):11018–11032. doi:10.18632/oncotarget.6920

 PubMedGoogle Scholar

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025

 PubMed Web of Science ®Google Scholar

Bellomo C, Caja L, Moustakas A. Transforming growth factor beta as regulator of cancer stemness and metastasis. Br J Cancer. 2016;115(7):761–769. doi:10.1038/bjc.2016.255

 PubMed Web of Science ®Google Scholar